If you have been reading about dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-03. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
== Metabolism == A cytochrome P450 enzyme is proposed to metabolize diethyl ether. Diethyl ether inhibits alcohol dehydrogenase, and thus slows the metabolism of ethanol. It also inhibits metabolism of other drugs requiring oxidative metabolism. For example, diazepam requires hepatic oxidization whereas its oxidized metabolite oxazepam does not.
ECD devices can be of two forms. It can trap analyte ions during the ECD stage or can undergo flow through mode where dissociation takes place as analyte ions flows continuously through the ECD region. Flow through mode has advantage over other mode because nearly all the analyte ion beam is used. However, that decreases the efficiency of ECD for flow through mode. ECD produces significantly different types of fragment ions (although primarily c- and z-type, b-ions have been identified in ECD) than other MS/MS fragmentation methods such as electron-detachment dissociation (EDD) (primarily a and x types), collision-induced dissociation (CID) (primarily b and y type) and infrared multiphoton dissociation. CID and IRMPD introduce internal vibrational energy in some way or another, causing loss of post-translational modifications during fragmentation. In ECD, unique fragments (and complementary to CID) are observed, and the ability to fragment whole macromolecules effectively has been promising. Although ECD is primarily used in Fourier transform ion cyclotron resonance mass spectrometry, investigators have indicated that it has been successfully used in an ion-trap mass spectrometer. ECD can also do rapid integration of multiple scans in FTICR-MS if put in a combination with external accumulation. ECD is a recently introduced MS/MS fragmentation technique and is still being investigated.
== Toxicity == The recommended therapeutic dose is 80-100 mg/m2 body area. Optimal dosage is determined based on measurements of unbound platinum concentration following intravenous infusion, combined with rate of creatine clearance as an assessment of renal function using Ishibashi’s formula: DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47 The exact mechanism of uptake into the cell is unknown, with information being considerably less available compared to cisplatin. What is known is that nedaplatin does not interact with the Oct2 or apical multidrug and toxin extrusion transporter (MATE) transporters, potentially explaining the difference in nephrotoxicity due to reduced accumulation in the proximal tubules of the kidney. Toxicogenomics has helped elucidate some of the mechanisms behind nephrotoxicity, where oxidative stress has been shown to deregulate gene expression via Hmox1 and other genes.
Sources: en.wikipedia.org
Thousands of customers of high street banks including HSBC, Nationwide, Barclays and Virgin Money are affected by payment problems following issues with a system that operates payments between individuals and firms. Princess Anne returns home from hospital following treatment for a head injury and concussion. Prime Minister Rishi Sunak releases a video condemning Andrew Parker, a Reform UK activist, for using a derogatory slur. Sunak mentions that he was called an "f-ing [fucking] Paki" by Parker, stating that "it was too important not to call out". Spain's Civil Guard confirms they have found the body of a British man from London who went missing while hiking in the Pyrenees on 24 June. 29 June – M&S announces plans to launch its own clothing repairs and alterations service starting in August. 30 June Spain's Civil Guard says it has called off its search for Jay Slater, who has been missing in Tenerife since 17 June. Euro 2024: England win 2–1 against Slovakia, taking them through to the quarter-finals. After Slovakia had led 1–0 for most of the game, Jude Bellingham scores and equalises in the fifth minute of the six-minute stoppage time, while captain Harry Kane scores the winning goal in the first minute of extra time.
Marfan syndrome (MFS) is a multisystemic genetic disorder that affects the connective tissue. People with the condition are often tall and thin, with long arms, legs, fingers, and toes. They also typically have exceptionally flexible joints and abnormally curved spines. The most serious complications involve the heart and aorta, with an increased risk of mitral valve prolapse and aortic aneurysm. The lungs, eyes, bones, and the covering of the spinal cord are also commonly affected. The severity of the symptoms is variable. MFS is caused by a mutation in FBN1, one of the genes that make fibrillin, which results in abnormal connective tissue. It is an autosomal dominant disorder. In about 75% of cases, it is inherited from a parent with the condition, while in about 25%, it is a new mutation. Diagnosis is often based on the Ghent criteria, family history, and genetic testing (DNA analysis). No cure for MFS is known. Many of those with the disorder have a normal life expectancy with proper treatment. Management often includes the use of beta blockers such as propranolol or atenolol, calcium channel blockers, ACE inhibitors, and/or angiotensin receptor blockers (ARBs). Surgery may be required to repair the aorta or replace a heart valve. Avoiding strenuous exercise is recommended for those with the condition. About one in 5,000 to 10,000 people have MFS. Rates of the condition are similar in different regions of the world. It is named after French pediatrician Antoine Marfan, who first described it in 1896.
Atkins, P.W., Overton, T., Rourke, J., Weller, M. and Armstrong, F. Shriver and Atkins Inorganic Chemistry (4th ed.) 2006 (Oxford University Press) ISBN 0-19-926463-5 Chang, Raymond. Chemistry 6th ed. Boston, Massachusetts: James M. Smith, 1998. ISBN 0-07-115221-0 Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. ISBN 978-0-19-850346-0. Tucker, William (2024). Chemistry: Energy, Matter, and Change. CRC Press. ISBN 9781003479338. Advanced undergraduate-level or graduate textbooks
Xi has formulated the new concept for development, stressing the importance of high-quality development rather than "inflated growth". He has stated China has abandoned a growth-at-all-costs strategy which Xi refers to as "GDP heroism". Instead, Xi said other social issues such as environmental protection are important. Xi has made eradicating extreme poverty through targeted poverty alleviation a key goal. In 2015, he launched the battle against poverty. The campaign concluded by 2021, when Xi declared a "complete victory" over extreme poverty, saying nearly 100 million have been lifted out of poverty under his tenure, though some experts said China's poverty threshold was lower than that of the World Bank. In 2020, premier Li Keqiang, citing the National Bureau of Statistics (NBS) said that China still had 600 million people living with less than 1000 yuan ($140) a month, although The Economist said the methodology NBS used was flawed. When Xi took office in 2012, 58% of people in China were living on less than $8.30 per day, in 2022 this had fallen to 21%. At the 19th Party Congress in 2017, Xi stated the primary contradiction of China's conditions in the new era as "the contradiction between the people's ever-growing need for a better life and unbalanced and inadequate development." In this context, "unbalanced" refers to rural-urban inequalities, regional inequalities, inequalities between the rich and poor, and structural imbalances in the economy. "Inadequate" refers to household income share.
Sources: en.wikipedia.org
Nordazepam (INN; marketed under brand names Nordaz, Stilny, Madar, Vegesan, and Calmday; also known as nordiazepam, desoxydemoxepam, and desmethyldiazepam) is a 1,4-benzodiazepine derivative. Like other benzodiazepine derivatives, it has amnesic, anticonvulsant, anxiolytic, muscle relaxant, and sedative properties. However, it is used primarily in the treatment of anxiety disorders. It is an active metabolite of diazepam, chlordiazepoxide, clorazepate, prazepam, pinazepam, and medazepam. Nordazepam is among the longest lasting (longest half-life) benzodiazepines, and its occurrence as a metabolite is responsible for most cumulative side-effects of its myriad pro-drugs when they are used repeatedly at moderate-high doses; the nordazepam metabolite oxazepam is also active (and is a more potent, full BZD-site agonist), which contributes to nordazepam cumulative side-effects but occur too minutely to contribute to the cumulative side-effects of nordazepam pro-drugs (except when they are abused chronically in extremely supra-therapeutic doses).
== Clinical application == In addition to endomorphins, morphine and morphine-like opiates target the μ-opioid receptor. Thus, endomorphins have significant potential as analgesics and morphine substitutes. In vitro assessment of endomorphins as analgesics reveals similar behavior to morphine and other opiates, where drug tolerance leads to dependence and addiction. Other side effects common to opiates such as vasodilation, respiratory depression, urinary retention, and gastrointestinal reaction develop. However, the endomorphin-induced side effects are slightly less severe than are those of the morphine-derived analgesics commonly used today. Additionally, endomorphins potentially produce more powerful analgesic effects than their morphine-derived counterparts. Despite their potential utility as pharmaceutical agents, the low membrane permeability and vulnerability to enzymatic degradation of endomorphins limit their incorporation into drugs. As a result, endomorphin analogues are being generated to allow transport across the blood brain barrier, increase stability, and reduce side effects. Two endomorphin modifications that approach these problems include glycosylation and lipidation. Glycosylation adds carbohydrate groups to the endomorphin molecules, allowing them to pass membranes via glucose transporters. Lipidation adds lipoamino acids or fatty acids to the endomorphin molecules, increasing hydrophobicity and, therefore, membrane permeability of the molecules.
== Ion cyclotron resonance heating == Ion cyclotron resonance heating (or ICRH) is a technique in which electromagnetic waves with frequencies corresponding to the ion cyclotron frequency is used to heat up a plasma. The ions in the plasma absorb the electromagnetic radiation and as a result of this, increase in kinetic energy. This technique is commonly used in the heating of tokamak plasmas.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.